Drug name - Ongentys
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8907099 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(4 years from now) | |
| US8168793 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(6 years from now) | |
| US9630955 | NEUROCRINE | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(10 years from now) | |
| CN101248064B | NEUROCRINE | Nitrate Group Scatechol Derivative As Comt Inhibitor |
Jul, 2026
(3 years from now) | |
| CN102816157B | NEUROCRINE | Nitrate Group Scatechol Derivative As Comt Inhibitor |
Jul, 2026
(3 years from now) | |
| CN102816157A | NEUROCRINE | Nitrate Group Scatechol Derivative As Comt Inhibitor |
Jul, 2026
(3 years from now) | |
| CN101248064A | NEUROCRINE | Nitrocatechol Derivatives As Comt Inhibitors |
Jul, 2026
(3 years from now) | |
| IN200801612P1 | NEUROCRINE | Nitrocatechol Derivatives As Comt Inhibitors |
Jul, 2026
(3 years from now) | |
| IN268246B | NEUROCRINE | Nitrocatechol Derivatives As Comt Inhibitors |
Jul, 2026
(3 years from now) | |
| IN201401357P3 | NEUROCRINE | Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor |
Dec, 2032
(10 years from now) | |
| IN326913B | NEUROCRINE | Chemical Compound Useful As Intermediate For Preparing A Catechol-O- Methyltransferase Inhibitor |
Dec, 2032
(10 years from now) | |
| EP1907382A1 | NEUROCRINE | Nitrocatechol Derivatives As Comt Inhibitors |
Jul, 2020
(2 years ago) | |
| EP1907382B1 | NEUROCRINE | Nitrocatechol Derivatives As Comt Inhibitors |
Jul, 2020
(2 years ago) | |
| EP2791134B1 | NEUROCRINE | Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor |
Dec, 2032
(10 years from now) | |
| EP2791134A1 | NEUROCRINE | Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor |
Dec, 2032
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9550759 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(3 years from now) | |
| US9745290 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Oct, 2027
(5 years from now) | |
| US8524746 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Jul, 2029
(6 years from now) | |
| US10583130 | NEUROCRINE | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(7 years from now) | |
| US10071085 | NEUROCRINE | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(7 years from now) | |
| US10357468 | NEUROCRINE | Medicaments for slowing Parkinson's disease |
May, 2035
(12 years from now) | |
Drugs and Companies using OPICAPONE ingredient
Treatment: Method of inhibiting comt in the periphery; method of treating parkinson's disease; method of reducing o-methylation of l-dopa; Method of treating parkinson's disease; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 25MG | CAPSULE;ORAL | Prescription |
| 50MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.